UK-based Achilles Therapeutics has announced the closing of its £100m Series B financing round, which was led by new investor RA Capital Management and founding investor Syncona.
Swiss drugmaker Roche’s push into personalised cancer medicines hit a milestone with Japanese approval of a new drug, Rozlytrek, that targets patients who must be identified via genetic profiling.